Newsletter Tool

PM Tracker

Today’s Big News

Aug 28, 2024

With phase 3 win, Novartis pads case for broader use of heart med Leqvio

UPDATE: Genentech telegraphs 93 layoffs in California after sharing plans to shutter cancer immunology research unit

FDA approves Illumina’s tumor biomarker test as a pan-cancer companion diagnostic

Controlled chaos: Method to design disordered proteins could open door to new therapies

In key win for GSK, Delaware court will review decision to allow expert testimony in Zantac cases

Bayer pens $547M biobucks pact with biotech pushing the boundaries of noncoding RNA

Novartis taps Lindy to turn biologic drugs into at-home injectables, puts nearly $1B on the line

Featured

With phase 3 win, Novartis pads case for broader use of heart med Leqvio

By Zoey Becker

After a positive phase 3 readout, Novartis said it aims to apply cholesterol-lowering Leqvio across the "full spectrum" of atherosclerotic cardiovascular disease.

UPDATE: Genentech telegraphs 93 layoffs in California after sharing plans to shutter cancer immunology research unit

By Fraiser Kansteiner

Genentech will lay off 93 employees in South San Francisco starting in early October, according to a Worker Adjustment and Retraining Notification alert in California. The downsizing campaign will kick off in the fall and run through December.

FDA approves Illumina’s tumor biomarker test as a pan-cancer companion diagnostic

By Conor Hale

The TruSight Oncology Comprehensive test screens solid tumor samples for 517 genes, to help identify who may benefit from specific immunotherapies.

Controlled chaos: Method to design disordered proteins could open door to new therapies

By Darren Incorvaia

Proteins are made of chains of amino acids, and a basic tenet of biology is that the sequence of amino acids determines how a protein folds into a 3D shape which, in turn, dictates the protein’s function. But another tenet of biology is that rules are meant to be broken.

In key win for GSK, Delaware court will review decision to allow expert testimony in Zantac cases

By Kevin Dunleavy

The Delaware Supreme Court has upheld a GSK appeal, deciding to review the state’s Superior Court decision to allow expert testimony that would support 75,000 personal injury Zantac lawsuits that have been consolidated in the state.

Bayer pens $547M biobucks pact with biotech pushing the boundaries of noncoding RNA

By James Waldron

The company has signed a deal worth over half a billion biobucks to partner up on two programs with NextRNA Therapeutics.

Novartis taps Lindy to turn biologic drugs into at-home injectables, puts nearly $1B on the line

By Angus Liu

Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs.

UK unveils plans to plug up to $527M into clinical trials, manufacturing and more

By Fraiser Kansteiner

The investment program, which combines the powers of the U.K.'s Department of Health and Social Care, England’s National Health Service and local trade group ABPI, has snared an up to 400-million-pound sterling ($527 million) investment to help accelerate patient access to cutting-edge drugs, bolster clinical trials and improve medicines manufacturing in the country.

Neurocrine’s KarXT rival hits in phase 2 schizophrenia trial—but only at lowest dose

By Nick Paul Taylor

Neurocrine Biosciences has achieved its hoped-for profile in a phase 2 schizophrenia trial, delivering its targeted level of efficacy with a lower rate of gastrointestinal adverse events than Bristol Myers Squibb’s KarXT. But the biotech only saw efficacy at the lowest dose—the three higher doses all failed.

After obesity, Pfizer and Flagship pick 2 more targets for multibillion-dollar partnership

By Gabrielle Masson

Flagship Pioneering and Pfizer have added Quotient into their 10-program partnership, inking a deal to discover new targets for two programs in cardiovascular and renal diseases.

Fierce podcasts

Don’t miss an episode

The TROP2 race for supremacy

In this week’s episode of “The Top Line,” Fierce executive editor Eric Sagonowsky chats with Angus Liu about his feature story on the three TROP2 front-runners.

A closer look at Fierce Biotech's Fierce 15

The future of health AI: Local governance, national standards

Resources

Whitepaper

Epilepsy Clinical Trials

Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.